“We have built considerable expertise in GLP-1 drug development through our oral peptide programs”
This week, Speak Pharma interviews Dr. Andrew Lewis,
Chief Scientific Officer at Quotient Sciences, a drug development and man...
“Our Translational Pharmaceutics platform shortens drug development timelines by over 12 months”
This week, SpeakPharma interviews John McDermott, Vice
President of Scientific Consulting at Quotient Sciences, a drug develop...
“Quotient Sciences’ integrated approach to drug development accelerates molecules to IND & beyond”
This week,
SpeakPharma interviews Eleanor Row, Executive Director of Commercial at Quotient Sciences, a global drug developmen...